摘要
目的评估索拉非尼联合经肝动脉化疗栓塞术(TACE)治疗原发性肝癌的疗效和安全性。方法回顾性分析在中国医科大学附属第一医院介入放射科行索拉非尼系统治疗并联合TACE治疗的10例不可切除肝癌患者的临床资料,按照修订的实体瘤疗效评估标准评价疗效,采用Kaplan-Meier法分析患者生存情况,采用美国国立癌症研究所常见毒性反应分级标准3.0版评价安全性。结果 10例患者中,2例为完全缓解,3例为部分缓解,3例为疾病稳定,2例为疾病进展,中位总生存期为29.5个月。有9例出现不同程度的不良反应,均为3级或以下级别,最常见的不良反应为手足皮肤反应(7/10)和腹泻(6/10)。结论索拉非尼联合TACE治疗原发性肝癌是一种安全、有效的治疗方法。
Objective To evaluate the efficacy and safety of the combination of sorafenib and transarte- rial chemoembolization （TACE） in the treatment of primary hepatocellular carcinoma （HCC） . Methods The clinical data of 10 patients with unresectable HCC treated by sorafenib combined with TACE in the Department of Radiology, the First Hospital of China Medical University were retrospectively analyzed. The efficacy was evalua- ted according to the modified Response Evaluation Criteria in Solid Tumors assessment. Survival was analyzed by Kaplan-Meier method. Safety was evaluated according to the National Cancer Institute Common Toxicity Criteria for Adverse Events version 3.0. Results Among the 10 patients, 2 achieved complete response, 3 achieved partial response, 3 achieved stable disease, and 2 experienced progressive disease. The median overall survival of the cohort was 29.5 months. Different degree of adverse drug reactions （ADRs） occurred in 9 patients but all were at grade 3 or lower. The most common ADRs were hand-foot skin reaction （7/10） and diarrhea （6/10）.Conclusion The combination of sorafenib and TACE is an effective and safe treatment for HCC.
出处
《中国医学科学院学报》
CAS
CSCD
北大核心
2014年第1期33-36,共4页
Acta Academiae Medicinae Sinicae
基金
国家高技术研究发展计划(863计划)(2012AA022701)
辽宁省科学技术计划项目(2013225585)~~
关键词
肝细胞癌
索拉非尼
化学栓塞
治疗结果
存活率
hepatocellular carcinoma
sorafenib
chemoembolization
treatment outcome
survival rate
